載入中
NYSEHealthcareMedical - Instruments & Supplies
最新資料
US$19.40
+US$0.19 · +0.99%
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
前收盤價
US$19.40
+US$0.19 · +0.99%
盤中時間採用ET。市場資料可能有所延遲。
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
日內區間
目前US$19.40
52週區間
目前US$19.40
盤中時間採用ET。市場資料可能有所延遲。
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
日內區間
目前US$19.40
52週區間
目前US$19.40
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 11.39億 EUR | 11.04億 EUR | 10.85億 EUR | 9.84億 EUR | 8.44億 EUR |
| 銷貨成本 | 8.09億 EUR | 8.02億 EUR | 7.45億 EUR | 6.64億 EUR | 5.79億 EUR |
| 毛利 | 3.3億 EUR | 3.02億 EUR | 3.4億 EUR | 3.2億 EUR | 2.65億 EUR |
| 研究與開發 | 2439.75萬 EUR | 3166.8萬 EUR | 3567.2萬 EUR | 3438.7萬 EUR | 2961.6萬 EUR |
| 銷售、一般及管理費用 | 1.23億 EUR | 1.19億 EUR | 1.14億 EUR | 1.12億 EUR | 8295萬 EUR |
| 營業費用 | 1.47億 EUR | 1.41億 EUR | 1.39億 EUR | 1.27億 EUR | 1.03億 EUR |
| 利息收入 | 1248.69萬 EUR | 172.3萬 EUR | 79.2萬 EUR | 64.8萬 EUR | 54.8萬 EUR |
| 利息支出 | 2180.41萬 EUR | 686.4萬 EUR | 431.5萬 EUR | 393.6萬 EUR | 487.1萬 EUR |
| 折舊和攤銷 | 8856.6萬 EUR | 8065.2萬 EUR | 7848萬 EUR | 6482.3萬 EUR | 5638.2萬 EUR |
| 營業利益 | 1.83億 EUR | 1.61億 EUR | 2.01億 EUR | 1.92億 EUR | 1.62億 EUR |
| 淨利 | 1.34億 EUR | 1.18億 EUR | 1.46億 EUR | 1.43億 EUR | 1.34億 EUR |
公司資料更新於 2026年10月10日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$25.58
上漲空間 31.86%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB740.09萬0.07%102.79億 USD0.44%US$206.49+3.00%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP139.61萬0.05%26.06億 USD0.20%US$66.35+1.13%
Baron ETF Trust - Baron SMID Cap ETFBCSM58.81萬1.64%3315萬 USD0.75%US$24.7647+1.35%
Acuitas Small Cap Active ETFAIMS55.41萬0.66%8428萬 USD0.75%US$27.0872+0.39%
State Street SPDR US Small Cap Low Volatility Index ETFSMLV35.34萬0.14%2.46億 USD0.12%US$151.37-0.09%
Infrastructure Capital Small Cap Income ETFSCAP27.81萬1.56%1790萬 USD2.20%US$35.75-0.18%
Baron ETF Trust - Baron Global Durable Advantage ETFBCGD16.12萬1.65%977萬 USD0.75%US$26.645+1.11%
American Century Small Cap Growth Insights ETFACSG14.47萬0.28%5142.32萬 USD0.49%US$46.29+1.24%iShares Biotechnology ETFIBBState Street SPDR S&P Kensho New Economies Composite ETFKOMPBaron ETF Trust - Baron SMID Cap ETFBCSMAcuitas Small Cap Active ETFAIMSState Street SPDR US Small Cap Low Volatility Index ETFSMLVInfrastructure Capital Small Cap Income ETFSCAPBaron ETF Trust - Baron Global Durable Advantage ETFBCGDAmerican Century Small Cap Growth Insights ETFACSGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
